A simple, accurate and precise RP-HPLC method was developed for the simultaneous determination of chloroquine, pyrimethamine and cetirizine hydrochloride concentrations in bulk drug and human serum. The assay was performed using a mobile phase of methanol: water (70:30) at pH of 2.8 ± 0.05 on the Purospher C-18 column with UV detection at 230 nm and rosuvastatin used as an internal standard. The retention times observed for chloroquine, pyrimethamine and cetirizine hydrochloride were 3.5, 2.5 and 5.5 minutes, respectively. The method was found to be specific for the assayed drugs showing a linear response in the concentration range of 1-100 μg mL-1 with coefficients of determination values of (r = 0.999). The method was developed and validated according to ICH guidelines. The method was used to monitor the serum samples and was found to be sensitive for therapeutic purposes, showing the potential to be a useful tool for routine analysis in laboratories.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/chromsci/bmab018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic surveillance shows spread of ACT resistance during period of malaria decline in Vietnam (2018-2020).
Front Genet
December 2024
Biomedical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium.
Introduction: Vietnam's goal to eliminate malaria by 2030 is challenged by the further spread of drug-resistant malaria to key antimalarials, particularly dihydroartemisinin-piperaquine (DHA-PPQ).
Methods: The custom targeted NGS amplicon sequencing assay, AmpliSeq Pf Vietnam v2, targeting drug resistance, population genetic- and other markers, was applied to detect genetic diversity and resistance profiles in samples from 8 provinces in Vietnam (n = 354), in a period of steep decline of incidence (2018-2020). Variants in 14 putative resistance genes, including and , were analyzed and within-country parasite diversity was evaluated.
Setting Up an NGS Sequencing Platform and Monitoring Molecular Markers of Anti-Malarial Drug Resistance in Djibouti.
Biology (Basel)
November 2024
Unité de Biologie Moléculaire, Hôpital Général de Peltier, Centre Hospitalier Universitaire de Djibouti, Avenue Marechal, Djibouti ville 98230, Djibouti.
Djibouti is confronted with malaria resurgence, with malaria having been occurring in epidemic proportions since a decade ago. The current epidemiology of drug-resistant is not well known. Molecular markers were analyzed by targeted sequencing in 79 clinical isolates collected in Djibouti city in 2023 using the Miseq Illumina platform newly installed in the country.
View Article and Find Full Text PDFExploring the relationship between genetic diversity and antimalarial drugs resistance markers in a malaria-endemic region of Burkina Faso.
Pan Afr Med J
November 2024
Université Joseph KI-ZERBO (UJKZ), Ouagadougou, Burkina Faso.
Introduction: the diversity of Plasmodium falciparum genotypes affects the dynamics of malaria transmission and is thought to be one of the factors hampering malaria control efforts. This study aimed to investigate the relationship between Plasmodium falciparum genetic diversity and chloroquine and sulfadoxine-pyrimethamine resistance markers in malaria endemic areas of Burkina Faso.
Methods: in a cross-sectional study, populations residing in Nouna health district were randomly recruited.
Background: Malaria in pregnancy is a major public health issue, particularly among vulnerable populations in malaria-endemic sub-Saharan African countries. To mitigate its risks, WHO recommends sulphadoxine-pyrimethamine (SP) for chemoprevention and artemisinin-based combination therapy (ACT) to treat uncomplicated malaria. These interventions have helped to alleviate the risk associated with malaria in pregnancy; however, in the context of the emergence of SP- and ACT-resistant , maintained efficacy is under threat.
View Article and Find Full Text PDFArticle Synopsis
- In 2014, a significant mutation linked to artemisinin resistance, known as K13 561H, was first detected in Rwanda, making it crucial to monitor its spread.
- Researchers utilized advanced blood preservation and pooled sequencing methods to assess the frequency of this mutation across multiple sites in Rwanda and neighboring countries from May 2022 to March 2023.
- Results showed that K13 561H and 675V mutations were prevalent in Rwanda, with concerning additional mutations emerging, signaling threats to malaria treatment efficacy and control efforts in the region.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!